DocWire News Editors

DocwireNews

CT-P10 (Truxima&trade;, Celltrion Healthcare), a biosimilar to anti-CD20 antibody rituximab, was therapeutically equivalent and had a similar safety profile to rituximab when given as a monotherapy in patients with low tumor burden follicular lymphoma, according to the results of a phase III, double-blind trial presented at the 60th ASH Annual Meeting and Exposition.In the study, 258 patients with low tumor burden follicular lymphoma were randomly assigned to receive CT-P10 or rituximab (375 mg/m2&nbsp;intravenously) as monotherapy weekly for 4 weeks as induction therapy, followed by maintenance therapy every 2 months for 2 years. To be eligible for maintenance therapy, patients had to achieve complete response, unconfirmed complete response, partial response, or stable disease after induction therapy.The majority of patients on both arms completed up to 7 months of treatment&mdash;119/130 (92%) of those assigned CT-P10 and 112/128 (88%) assigned rituximab. The primary endpoint for this portion of the trial was overall response rate (ORR) over 7 months, and was similar in both treatment arms. Patients assigned to CT-P10 had an ORR of 83.1% compared with 81.3% for rituximab.CT-P10 was also well tolerated, according to study researcher Michinori Ogura, MD, PhD, of Kasugai Municipal Hospital in Konan, Japan, and colleagues. Both agents had a similar safety profile, and the researchers observed no new safety findings. Adverse event rates were 71% with CT-P10 and 67% with rituximab. Infections and infusion-related reactions occurred in a similar proportion of patients in both groups, and no patients experienced progressive multifocal leukoencephalopathy or hepatitis B virus reactivation.On November 28, the U.S. Food and Drug Administration approved CT-P10 as the first biosimilar to rituximab for the treatment of adult patients with CD20-positive, B-cell non-Hodgkin lymphoma (NHL) to be used as a single agent or in combination with chemotherapy. In February 2017, the European Medicines Agency approved it for use in all indications for which rituximab is approved, including follicular lymphoma, diffuse large B-cell NHL, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis.

Jayme Locke, MD, MPH

Joel M. Topf, MD, FACP

The Promise of Xenotransplantation

NKF Spring Clinical Meetings 2025

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Sacituzimab Govitecan Showed Modest Activity for CNS Metastases

Triple-Negative Breast Cancer

Latest News

Rituximab Biosimilar Proves Equivalence as Monotherapy in Follicular Lymphoma

ASH Annual Meeting 2018

CT-P10 (Truxima™, Celltrion Healthcare), a biosimilar to anti-CD20 antibody rituximab, was therapeutically equivalent and had a similar safety profile to rituximab when ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe